Delving into the Latest Updates on Chlorotrianisene with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Chloortrianisestrol, Chlorestrolo, Chlorotrianisene (INN)

+ [8]

Target

ER

Mechanism

ERs agonists(Estrogen receptors agonists)

Therapeutic Areas

Endocrinology and Metabolic DiseaseUrogenital Diseases

Active Indication

HypogonadismProstatic HyperplasiaUterine Hemorrhage

Inactive Indication

Hepatocellular Carcinoma

Originator Organization

Suzhou First Pharmaceutical Co., Ltd.

Active Organization

Suzhou First Pharmaceutical Co., Ltd.

Inactive Organization

Shenzhen SiBiono GeneTech Co. Ltd.Sanofi-Aventis, Inc.Banner Pharmacaps BV

Drug Highest PhaseApproved

First Approval Date

CN (01 Jan 1984),

HypogonadismProstatic HyperplasiaUterine Hemorrhage

Regulation-

Login to view timeline

Structure

Molecular FormulaC23H21ClO3

InChIKeyBFPSDSIWYFKGBC-UHFFFAOYSA-N

CAS Registry569-57-3

Stereotactic body radiation therapy (SBRT) is an emerging treatment for hepatocellular carcinoma (HCC), which provides excellent local control (LC) and prolongs overall survival (OS). However, in current guidelines, transcatheter arterial chemoembolization (TACE) has been proposed as a key treatment option for patients with early- and intermediate-stage HCC, whereas SBRT is not. Therefore, we performed a systematic review and meta-analysis of randomized controlled trials and retrospective studies using the propensity score (PS) to compare the outcomes of SBRT and TACE for HCC in a balanced manner. We systematically searched the PubMed, Cochrane, EMBASE, and Web of Science databases to identify randomized controlled trials and studies comparing SBRT and TACE using PS analysis. The hazard ratios (HRs) for OS and LC were pooled. The heterogeneity between the data collected from these studies was also assessed. SBRT led to a comparable OS (HR: 0.83; 95 % confidence interval (CI): 0.52-1.34; p = 0.44) to TACE, and significantly improved LC (HR: 0.25; 95 % CI: 0.09-0.67; p = 0.006). Considerable heterogeneity was observed in the HR of OS and LC. Although there was no significant difference in the rate of grade 3 or higher toxicities between TACE and SBRT, or between studies, liver toxicity was identified as a common adverse event associated with both SBRT and TACE. Compared to TACE, SBRT showed a comparable OS and improved LC without serious toxicity. Therefore, SBRT should be considered an effective treatment option for various stages of HCC, depending on the tumor factors and pretreatment liver function.

31 Dec 2024·ANNALS OF MEDICINE

Transarterial chemoembolization combined with molecular targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma beyond the up-to-seven criteria: a propensity score-matching analysis

Article

Author: Zhou, Chun-Gao ; Liu, Jin ; Zhang, Jin-Xing ; Liu, Sheng ; Chen, Wen ; Yan, Hai-Tao ; Cheng, Yuan ; Zu, Qing-Quan ; Shi, Hai-Bin

PURPOSE:

Not all patients benefit from transarterial chemoembolization (TACE) due to the heterogeneity of the tumour burden in intermediate-stage hepatocellular carcinoma (HCC). To compare the outcomes of transarterial chemoembolization (TACE) combined with molecular-targeted agents plus immune checkpoint inhibitors (TACE-MTAs-ICIs) with those of TACE for patients with unresectable hepatocellular carcinoma (uHCC) that were beyond the up-to-seven criteria.

PATIENTS AND METHODS:

Between January 2019 and July 2022, 130 patients diagnosed with uHCC beyond the up-to-seven criteria were retrospectively identified, including 47 patients who received TACE-MTAs-ICIs and 83 patients who received TACE alone. The primary endpoints were overall survival (OS) and progression-free survival (PFS); the secondary endpoints included tumour response and adverse events (AEs).

RESULTS:

There were 43 matched patients. The median OS and PFS times in the TACE-MTAs-ICIs group were significantly longer than those in the TACE group (OS: 27.2 vs. 15.9 months, p = 0.007; PFS: 15.4 months vs. 4.8 months, p < 0.001). The objective response rate (ORR) in the TACE-MTAs-ICIs group was higher than that in the TACE group (65.1% vs. 37.2%, p = 0.010). Reversible AEs (grade 3 or 4) occurred differently in TACE-MTAs-ICIs and TACE groups (83.7% vs. 51.2%, p = 0.001). Univariate and multivariate analyses revealed that TACE-MTAs-ICIs treatment was an independent favourable prognostic factor for both PFS and OS (p < 0.001).

CONCLUSION:

For uHCC patients beyond the up-to-seven criteria, TACE-MTAs-ICIs provided superior ORR and OS. Early combined TACE and systemic treatment should shift for patients who are beyond these criteria.

01 Dec 2024·Asian Journal of Surgery

Survival benefit from adjuvant TACE combined with lenvatinib for patients with hepatocellular carcinoma and microvascular invasion after curative hepatectomy

Article

Author: Gao, Zhen-Yu ; Shen, Guo-Liang ; Liang, Lei ; Liu, Jun-Wei ; Zhang, Cheng-Wu ; Wang, Kai-Di ; Huang, Dong-Sheng ; Dai, Mu-Gen ; Xu, Zhu-Ding ; Du, Cheng-Fei ; Ye, Tai-Wei ; Liu, Si-Yu ; Lu, Wen-Feng ; Huang, Xiao-Kun

BACKGROUND AND AIMS:

The prognosis of patients with hepatocellular carcinoma (HCC) undergoing hepatectomy is unsatisfactory, especially for those with microvascular invasion (MVI). This study aimed to determine the impact of adjuvant transcatheter arterial chemoembolization (TACE) and Lenvatinib on the prognosis of patients with HCC and MVI after hepatectomy.

METHODS:

Patients diagnosed with HCC and MVI were reviewed, and stratified into four groups according to adjuvant TACE and/or Lenvatinib. Multivariate Cox regression analyses are used to determine independent risk factors.

RESULTS:

346 patients were included, and divided into four groups (Group I, TACE+ Lenvatinib; Group II, Lenvatinib; Group III, TACE; Group IV, without adjuvant therapy). Multivariable analysis showed that compared to Group IV, Group I had the best effect on improving the overall survival (OS, HR 0.321, 95%CI 0.099-0.406, P = 0.001) and recurrence-free survival (RFS, HR 0.319, 95%CI 0.129-0.372, P = 0.001). Additionally, compared with Group II or Group III, Group I also can significantly improve the OS and RFS. There is no significant difference between Group II and Group III in OS and RFS.

CONCLUSION:

The combination of TACE and Lenvatinib should be considered for anti-recurrence therapy for patients with HCC and MVI after hepatectomy.

2

News (Medical) associated with Chlorotrianisene

29 Jan 2024

·www.drugs.com

Addition of Durvalumab, Bevacizumab to TACE Beneficial in Liver Cancer

MONDAY, Jan. 29, 2024 -- For patients with embolization-eligible unresectable hepatocellular carcinoma (uHCC), the addition of durvalumab (D) and bevacizumab (B) to transarterial chemoembolization (TACE) improves progression-free survival (PFS), according to a study presented at the American Society of Clinical Oncology annual Gastrointestinal Cancers Symposium, held from Jan. 18 to 20 in San Francisco. Riccardo Lencioni, M.D., from the University of Pisa School of Medicine in Italy, and colleagues randomly assigned patients with embolization-eligible uHCC to D + B + TACE, D + TACE, or TACE in a 1:1:1 ratio (204, 207, and 205 patients, respectively). The primary end point was PFS for D + B + TACE versus TACE. The researchers found that PFS was significantly improved for D + B + TACE versus TACE (median, 15.0 versus 8.2 months; hazard ratio, 0.77). Across most prespecified subgroups, the results were consistent. The secondary end point of PFS for D + TACE versus TACE did not reach statistical significance. The objective response rate was 43.6, 41.0, and 29.6 percent, respectively, and median time to progression was 22.0, 11.5, and 10.0 months, respectively, for D + B + TACE, D + TACE, and TACE. Maximum grade 3/4 treatment-related adverse events occurred in 32.5, 15.1, and 13.5 percent, respectively; 0, 1.3, and 2.0 percent, respectively, died due to treatment-related adverse events. "These results of the EMERALD-1 trial have the potential to establish a new standard of care for the treatment of unresectable hepatocellular carcinoma," Cathy Eng, M.D., ASCO expert in gastrointestinal cancers, said in a statement. Several authors disclosed ties to pharmaceutical companies, including AstraZeneca, which manufactures durvalumab and funded the study. Press Release More Information Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions. Posted January 2024 More news resources FDA Medwatch Drug Alerts Daily MedNews News for Health Professionals New Drug Approvals New Drug Applications Drug Shortages Clinical Trial Results Generic Drug Approvals Subscribe to our newsletter Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical ResultASCOClinical Study

19 Jan 2024

·firstwordpharma.com

EMERALD-1 readout dulls Imfinzi's sheen in first-line liver cancer

AstraZeneca's immunotherapy Imfinzi (durvalumab) produced a mixed bag when used as an add-on to transarterial chemoembolisation (TACE) in patients with hepatocellular carcinoma (HCC). According to detailed results from the Phase III EMERALD-1 trial, unveiled Friday at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), the combination significantly improved progression-free survival (PFS), but only when Roche's Avastin (bevacizumab) was part of the mix.PFS benefit of nearly 7 monthsThe three-arm study included 616 patients with embolisation-eligible unresectable HCC who were randomised to receive TACE therapy alone, or Imfinzi plus TACE either with or without Avastin. AstraZeneca said the trio combination reduced the risk of disease progression or death by a statistically significant 23%, compared to placebo plus TACE. Median PFS for the two groups was 15 months and 8.2 months, respectively.However, without Avastin, there was no significant PFS difference between those who received Imfinzi plus TACE and the TACE-only groups. Researchers said objective response rate (ORR) and time to progression (TTP) were also superior in the Imfinzi, Avastin and TACE arm. The ORR for these patients was 43.6% and median TTP was 22 months, whereas it was 29.6% and 10 months for TACE-only.Will it be enough?Susan Galbraith, who heads oncology R&D at AstraZeneca, said "we are discussing these positive EMERALD-1 data with global regulatory authorities while awaiting the final overall survival (OS) results from the trial."At the company's earnings call last November, Galbraith said it would be "important for us to show the potential for contribution of components" in the treatment regimen. She also noted that OS data would be key given the EMERALD-1 study's focus is in the locoregional setting, although "it may well be possible to file on PFS, and then wait for OS to be supplemented during the follow-up period and during the review period."Imfinzi is currently approved in combination with Imjudo (tremelimumab) for unresectable HCC in the US, Europe, Japan, China and other countries based on the Phase III TOPAZ-1 and HIMALAYA Phase III trials. The PD-L1 inhibitor is also approved for other indications including non-small-cell lung cancer, extensive-stage small cell lung cancer and advanced biliary tract cancer.

Clinical ResultPhase 3ASCODrug ApprovalImmunotherapy

100 Deals associated with Chlorotrianisene

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00269	Chlorotrianisene	G03CA06	DB00269

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hypogonadism	CN	Suzhou First Pharmaceutical Co., Ltd.	01 Jan 1984
Prostatic Hyperplasia	CN	Suzhou First Pharmaceutical Co., Ltd.	01 Jan 1984
Uterine Hemorrhage	CN	Suzhou First Pharmaceutical Co., Ltd.	01 Jan 1984

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatocellular Carcinoma	Phase 2	CN	Shenzhen SiBiono GeneTech Co. Ltd.	01 Jul 2014

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2024	Not Applicable	Unresectable Hepatocellular Carcinoma First line	-	TACE (Surgical resection (SR))	bpgwqmltzn(wucwrysbxv) = juojbrmsjy qremgsqaxt (pezfgoaqxn ) View more	Positive	24 May 2024
				TACE (Thermal ablation (TA))	bpgwqmltzn(wucwrysbxv) = lphoeyuykt qremgsqaxt (pezfgoaqxn ) View more
ASCO2024	Not Applicable	Unresectable Hepatocellular Carcinoma	-	Dona-TACE	mmjtnhdapb(zrzckmjyum) = iqgqeotpyv beqwtazvum (altgicutox ) View more	Positive	24 May 2024
				Lenva-TACE	mmjtnhdapb(zrzckmjyum) = wvuickxlmi beqwtazvum (altgicutox ) View more
EASL_LCS2024	Not Applicable	-	-	TKIs (sorafenib)	icqorgmsxj(yqvgcswddq) = wnyshythhc ktybrajzjd (rovwyzvaxn )	-	22 Feb 2024
				TACE (doxorubicin+DC-beads)	icqorgmsxj(yqvgcswddq) = obpqljluau ktybrajzjd (rovwyzvaxn )
ASCO2023	Not Applicable	Advanced Hepatocellular Carcinoma Second line	43	TACE+Regorafenib	czzocubjpe(eyrlzyhszx) = 16.28% byfyifeshx (guiyictvhd ) View more	Positive	31 May 2023
CSCO2021	Not Applicable	Liver Cancer	53	TACE联合国产PD-1抑制剂及仑伐替尼	qwjdlayqyr(tkknrdrbvz) = nouphjtzpf xiedhtspeb (gffnrlgrhd ) View more	Positive	25 Sep 2021
CSCO2021	Not Applicable	Liver Cancer	107	TACE+MWA联合治疗组	rntptwpxku(gwicaddwea) = pylhpjndbd myebwdbvre (ecnnarogfn ) View more	-	25 Sep 2021
				单纯TACE组	rntptwpxku(gwicaddwea) = arzveubttr myebwdbvre (ecnnarogfn ) View more
CSCO2020	Not Applicable	Hepatocellular Carcinoma	323	TACE (BCLC B期)	mifsxflqwq(zizqzllvhr) = mixitpsakg gdgsipviyo (nhrktlfiia ) View more	-	19 Sep 2020
				TACE (BCLC C期)	mifsxflqwq(zizqzllvhr) = gotcaswlgi gdgsipviyo (nhrktlfiia ) View more
NCT03007225 (treatment of HCC, CTgov)	Phase 4	Hepatocellular Carcinoma	50	Doxorubicin hydrochloride (Group 1)	bzlnpjxhsb(vfqzlhwxdg) = agbjebrhxt fozggledrk (lbpvsjvnms, gwzjfdghkr - kfvgoulyjs) View more	-	17 Sep 2020
				Urografin+gentamycin+Doxorubicin hydrochloride+Lipiodol (Group 2)	bzlnpjxhsb(vfqzlhwxdg) = bwauqxpfsd fozggledrk (lbpvsjvnms, uswglqqvte - zzvrtivdch) View more
EASL2019	Not Applicable	Hepatocellular Carcinoma First line	-	TACE (Treatment-naive HCC (TN-HCC))	tnlpylkjrg(trxbdwsaea) = kytdpyswpb rnofuzgpfu (pxugpfjgin ) View more	Positive	12 Apr 2019
				TACE (Recurrent HCC after curative resection (R-HCC))	tnlpylkjrg(trxbdwsaea) = oziemhoqte rnofuzgpfu (pxugpfjgin ) View more
AACR2016	Not Applicable	Hepatocellular Carcinoma	59	TILA-TACE treatment	ohkyfbwfpx(icomszujqu) = muzpcvdggr lcwckjmbwn (wprmcvpnuk ) View more	Positive	15 Jul 2016